Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT05767346 is registered in ClinicalTrials.gov with Cytokinetics as lead sponsor.

NCT NCT05767346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05767346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Lead sponsor
Cytokinetics
Phase
Phase 3
Overall status
Completed
Start date
June 20, 2023
Completion date
March 28, 2025
Enrollment
175 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

obstructive hypertrophic cardiomyopathy (ohcm)